Why the study?
Does low dose recombinant human growth hormone replacement improve regional fat distribution, insulin sensitivity, and cardiovascular risk factors in nondiabetic hypopituitary adults?
Does low dose recombinant human growth hormone replacement improve regional fat distribution, insulin sensitivity, and cardiovascular risk factors in nondiabetic hypopituitary adults?
Low-dose GH replacement in hypopituitary adults improves central adiposity and lipid profiles but adversely decreases insulin sensitivity and increases lipoprotein-(a).
No takes yet. Share an insight, caveat, or question.
GH improves central adiposity and lipids yet impairs insulin sensitivity; extends RCT evidence on short-term metabolic trade-offs in hypopituitary adults.
Weaver et al. (1995) studied this question.